Linked Life Data

16282676

Source:http://linkedlifedata.com/resource/pubmed/id/16282676

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-12-19
pubmed:abstractText
Paricalcitol and doxercalciferol are effective in reducing parathyroid hormone PTH concentrations in patients with secondary hyperparathyroidism. The purpose of this study was to determine the relative dose of doxercalciferol (compared to paricalcitol) required to maintain equivalent PTH concentrations in dialysis patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0250-8095
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
591-5
pubmed:dateRevised
2007-2-14
pubmed:meshHeading
pubmed:articleTitle
Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.
pubmed:affiliation
Evanston Northwestern Healthcare, Division of Nephrology, Northwestern University Feinberg School of Medicine, 2650 Ridge Ave, IL 60201, USA.
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase IV